Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole

NCT05286437 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

Interventions

DRUG: Oral Lenvatinib + Intravenous (IV) Pembrolizumab + Oral Letrozole

Sponsor

National Cancer Centre, Singapore

Collaborators

[object Object]